Candel Therapeutics Inc (NASDAQ:CADL) announced that data from its Phase 3 trial of CAN-2409 for localized prostate cancer will be featured in an oral presentation at the 2025 ASCO Annual Meeting, held May 30–June 3 in Chicago.
The presentation, led by Dr. Theodore DeWeese of Johns Hopkins, will take place on June 3 during the Genitourinary Cancer session.
Full abstracts will be released May 22. Results will be available on Candel’s website after the event.